eShowcase: ViewPoint 3.6
Tools for Clinical Trials Professionals
Software provides complete visibility into the regulatory submission process
Octagon Research Solutions, Inc. (Wayne, PA) recently announced an update to its enterprise submission process management solution. Viewpoint 3.6 streamlines the regulatory submission process by affording visibility into the planning and management of the drug submission process and allows users to track, manage, and compile any type of regulatory application.
Viewpoint 3.6 Resource Estimator, Reviewer, and Regulatory Dashboard have been upgraded to provide enhanced workflow estimation, collaboration, and project tracking across the submission life cycle. The new Web-based Reviewer allows content contributors to view and validate their documents in the context of a submission. This, Octagon says, lessens the possibility that clinical trial professionals will miss a submission date or file an incomplete or noncompliant eCTD submission.
ViewPoint 3.6
Octagon Research Solutions, (610) 535-6500, www.octagonresearch.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
